News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Nektar Therapeutics Ovarian Cancer Drug Benefits Women in Study
June 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- About 48 percent of women with advanced ovarian cancer saw sustained benefits from treatment with Nektar Therapeutics' experimental drug NKTR-102 in a mid-stage study, the company said on Sunday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
Vaccines
HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space
April 29, 2025
·
2 min read
·
Tristan Manalac
Bladder cancer
Pfizer’s Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses Survival Endpoint
April 28, 2025
·
1 min read
·
Tristan Manalac
Bladder cancer
J&J Declares ‘Sustained Disease Control’ With Bladder Cancer Drug-Device Combo
April 28, 2025
·
2 min read
·
Tristan Manalac
Cancer
Perioperative Keytruda Cuts Risk of Negative Events by Over 25% in Head and Neck Cancer
April 28, 2025
·
1 min read
·
Tristan Manalac
